The 13th Aging Research & Drug Discovery (ARDD) Meeting, the world’s largest conference dedicated to longevity biotechnology, will take place from October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. Marking the high-profile launch of Boston Longevity Week, this landmark event is officially organized by Insilico Medicine, which also anchors the conference as a Tier 1 sponsor alongside Eli Lilly.
As longevity science rapidly transitions from theoretical concepts to multi-billion-dollar therapeutic pipelines, ARDD 2026 stands as the premier global nexus connecting basic science, clinical research, big pharma, and institutional investors. Moving the conference to Boston-the global epicenter of biomedical innovation-reflects the field’s evolution into mainstream medicine.
Building on the massive momentum of previous years-including ARDD 2025 in Copenhagen, where leadership from Eli Lilly and Novo Nordisk discussed the profound longevity potential of GLP-1 receptor agonists in Nature Biotechnology-the 2026 conference solidifies aging research as a core pillar of healthcare. Top-tier pharmaceutical companies are now actively developing commercial programs targeting fibrosis, immunology, CNS, cardiometabolic diseases, anti-muscle wasting, and cellular rejuvenation.